Step 6: Treatment Success--Suppressed Viral Load

Active Resources: 40

Image Library

Clinical Reference Tools

Patient Information

Articles: 6

  • Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference

    Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair

    The field of HIV/AIDS care and treatment continues to evolve rapidly. Groundbreaking developments in HIV research are regularly presented at international meetings and...

  • in+care Campaign Update: The Results are In

    National Quality Center (NQC) has completed its evaluation of the in+care Campaign -- the largest HIV quality improvement initiative carried out at the national level. We are pleased to announce that the Campaign demonstrated significant improvements in national retention and viral load...

  • Adult and Adolescent Guidelines: Major Changes

    The U.S. Department of Health and Human Services has released new treatment guidelines for adults and adolescents, and these contain some important changes. Key among these is a major shakeup in the "Recommended Regimen Options" for initial therapy. 

    Efavirenz/TDF/FTC (Atripla) has...
  • Some Thoughts on Building Capacity for the AETC Practice Transformation Projects

    While there are many unknowns about exactly what the AETCs will look like with the start of the new grant cycle later this year, one thing we do know is that Practice Transformation (PT) and Practice Facilitation will be a part of the work.  In fact about 40% of AETC resources will be devoted to...

  • Two New Boosted-PI Coformulations

    Two boosted protease inhibitor (PI) coformulations have just been approved by the FDA. These are:

    Darunavir 800 mg + cobicistat 150 mg (Prezcobix), andAtazanavir 300 mg + cobicistat 150 mg (Evotaz)

    In these fixed-dose combinations, cobicistat is used as the pharmacokinetic booster of the PI...

  • New Fixed-Dose Combination Pill: Dolutegravir + Abacavir + Lamivudine

    The FDA has approved the coformulation of the integrase inhibitor dolutegravir (50 mg) with the NRTIs abacavir (600 mg) and lamivudine (300 mg); its brand name is Triumeq. Triumeq is the first single-pill combination that does not include tenofovir.

    Dosing is...

Day Title
12/2
HIV Update for Rehab Facilities and Long Term Care
12/15
Behavioral Health Issues in HIV Management
Day Title
10/23
National Day of Action to End Violence Against Women with HIV
Event type: Awareness Days
10/17
Institute of Human Virology (IHV) Case Conference
6/5
HIV Long-Term Survivors Day
Event type: Awareness Days
3/7
Pediatric HIV/AIDS Training Course
2/13
CROI 2017: Seattle